Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Large Growth in Short Interest

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,720,000 shares, a growth of 13.2% from the December 31st total of 1,520,000 shares. Based on an average daily volume of 773,000 shares, the short-interest ratio is currently 2.2 days. Approximately 5.2% of the shares of the company are sold short.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of HOWL. American Century Companies Inc. raised its position in shares of Werewolf Therapeutics by 50.7% during the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after buying an additional 12,656 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Werewolf Therapeutics by 43.9% during the second quarter. Dimensional Fund Advisors LP now owns 160,577 shares of the company’s stock valued at $392,000 after buying an additional 48,952 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Werewolf Therapeutics by 103.1% during the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after buying an additional 86,800 shares during the last quarter. Marshall Wace LLP raised its position in shares of Werewolf Therapeutics by 410.5% during the second quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock valued at $327,000 after buying an additional 107,900 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Werewolf Therapeutics by 96.4% in the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after purchasing an additional 544,881 shares in the last quarter. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Performance

NASDAQ HOWL traded up $0.01 on Monday, reaching $1.35. 164,512 shares of the stock were exchanged, compared to its average volume of 271,389. Werewolf Therapeutics has a one year low of $1.26 and a one year high of $8.19. The firm has a market capitalization of $59.93 million, a PE ratio of -0.88 and a beta of 0.36. The company’s 50-day simple moving average is $1.58 and its two-hundred day simple moving average is $2.01. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th. JMP Securities decreased their target price on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 14th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.